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brain injury
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Abstract
Background: Acute traumatic brain injury (TBI) represents one of major causes of mortality and disability in the
USA. Neuroinflammation has been regarded both beneficial and detrimental, probably in a time-dependent fashion.
Methods: To address a role for neuroinflammation in brain injury, C57BL/6 mice were subjected to a closed head mild
TBI (mTBI) by a standard controlled cortical impact, along with or without treatment of sphingosine 1-phosphate (S1P) or
rolipram, after which the brain tissue of the impact site was evaluated for cell morphology via histology, inflammation by
qRT-PCR and T cell staining, and cell death with Caspase-3 and TUNEL staining. Circulating lymphocytes were quantified
by flow cytometry, and plasma hydrocortisone was analyzed by LC-MS/MS. To investigate the mechanism whereby
cortisol lowered the number of peripheral T cells, T cell egress was tracked in lymph nodes by intravital confocal
microscopy after hydrocortisone administration.
Results: We detected a decreased number of circulating lymphocytes, in particular, T cells soon after mTBI, which was
inversely correlated with a transient and robust increase of plasma cortisol. The transient lymphocytopenia might be
caused by cortisol in part via a blockade of lymphocyte egress as demonstrated by the ability of cortisol to inhibit T cell
egress from the secondary lymphoid tissues. Moreover, exogenous hydrocortisone severely suppressed periphery
lymphocytes in uninjured mice, whereas administering an egress-promoting agent S1P normalized circulating T cells in
mTBI mice and increased T cells in the injured brain. Likewise, rolipram, a cAMP phosphodiesterase inhibitor, was also able
to elevate cAMP levels in T cells in the presence of hydrocortisone in vitro and abrogate the action of cortisol in mTBI
mice. The investigation demonstrated that the number of circulating T cells in the early phase of TBI was positively
correlated with T cell infiltration and inflammatory responses as well as cell death at the cerebral cortex and hippocampus
beneath the impact site.
Conclusions: Decreases in intracellular cAMP might be part of the mechanism behind cortisol-mediated blockade
of T cell egress. The study argues strongly for a protective role of cortisol-induced immune suppression in the early
stage of TBI.
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Background
Acute traumatic brain injury (TBI) is a major cause of
mortality and disability in the early decades of life in
many developed countries. At least 5.3 million people in
the USA currently require long-term or life-long assist-
ance with the activities of daily living after TBI [1]. TBI
results in cerebral structural damage and functional defi-
cits due to both primary and secondary injury. The pri-
mary injury is caused directly by the external mechanical
force at the moment of trauma leading to skull fractures,
brain contusions, lacerations, diffused axonal injuries,
vascular tearing, intracranial hemorrhages, etc. The pri-
mary injury is followed by development of secondary
neuronal damage that evolves over a period of months
[2], thereby providing a golden opportunity for preven-
tion and intervention. Tremendous efforts have been
made in the past decades toward exploring the cellular
and molecular mechanisms underlying secondary brain
damage as well as identification of specific targets for
prevention and/or therapeutics against this disorder [2].
It is now believed that a cascade of molecular, neuro-
chemical, neuronal cell apoptosis, cellular, and immune
processes contribute to secondary brain damage as a
consequence of mitochondrial dysfunction, cerebral hyp-
oxia, and disruption of calcium homeostasis in cells at
the impact site [2, 3].
A growing body of evidence indicates that inflamma-
tion induced by primary brain injury plays dual and
opposite roles in the outcome of TBI [4]. On one hand,
it contributes to reparation and regeneration processes
of the primary brain injury, for instance, clearance of
necrotic and apoptotic cells by phagocytic cells and pro-
moting neuron growth at the injured site [5, 6]. On the
other hand, it facilitates secondary brain injury via the
production of various inflammatory cytokines such as
interleukin-1-alpha (IL-1α) and interleukin-1-β (IL-1β),
tumor necrosis factor alpha (TNF-α), and interleukin-6
(IL-6) [7, 8]. The brain is well known to be an immune
privilege site, and infiltration of inflammatory cells to it
is largely restricted by the blood-brain barrier (BBB)
under a physiological condition [9]. However, TBI often
results in an invasion of neutrophils, monocytes, and
lymphocytes from the periphery and activation of micro-
glia due to disruption of the BBB. This initiates a
cascade of inflammatory responses [10]. Likewise, T lym-
phocytes have been shown to infiltrate the brain paren-
chyma post-injury, but their role in the secondary brain
injury development following TBI remains poorly under-
stood [11].
Both pre-clinical and clinical studies have shown
significant, acute increases of cortisol levels in serum
and cerebrospinal fluid in response to TBI [12, 13]. The
increased cortisol might suppress inflammation in the
brain in order to protect the injured brain tissues from
inflammation insult, in light of the well-documented
anti-inflammatory function of cortisol, a steroid hor-
mone. The current investigation revealed that an
elevated level of serum cortisol was inversely correlated
with the number of peripheral lymphocytes, in particu-
lar, T cells following brain trauma. Cortisol appeared to
sequester lymphocytes in the secondary lymphoid tissues
by blocking their egress, contributing to reduced inflam-
mation and cell death at injured brain tissues. The study
sheds novel insight into the mechanism underlying
cortisol-mediated suppression of inflammation and pro-
tective roles of cortisol in TBI at the early stage.
Methods
Animals
Eight-week-old female C57BL/6 mice were purchased from
Charles River Laboratories and maintained in a 12-h light/
dark cycle. All animal experiments were approved by the
Institutional Animal Care and Use Committee (IACUC) of
the Massachusetts General Hospital and performed accord-
ing to the National Institutes of Health guidelines for the
Care and Use of Laboratory Animals.
TBI induction
Mice were subjected to a closed head TBI by a standard
controlled cortical impact on the left lateral with intact
skull and scalp as previously described [7, 14]. In brief,
the mice were anesthetized with isoflurane and placed
on a mobile plate with their hair removed from the head.
A flat face 2-mm diameter tip of the pneumatic impact
device (AMS 201, AmScien Instruments, Richmond, VA)
was positioned on the left hemisphere center, lowered
gradually down to touch the scalp, and recorded as zero
depth (sham control). The punch depth was then set
2 mm using a screw-mounted adjustment. A 4.9 ±
0.2 m/s velocity and 80 ms contact time were specified
by setting 150 pounds per square inch (psi) for a high
pressure and 30 psi for a low pressure impact. These pa-
rameters were selected to yield a trauma giving rise to a
neurological severity score (NSS) of 3–5 at 1 h post-TBI
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also called mild TBI (mTBI). After recovery from
anesthesia, the mice were returned to cages with post-
operative care.
Quantification of circulating lymphocytes
Blood samples were collected from tail vein in 1 and 4 h
after TBI to assess plasma cortisol and circulating lym-
phocytes or 4 h after hydrocortisone injection (Sigma,
10 mg/kg) to confirm suppressive effects of cortisol on
peripheral leukocytes. In separate groups of mice, TBI
was induced as above, immediately followed with i.p.
injection of either sphingosine 1-phosphate (S1P) (Enzo
Life Sciences, 5 μM/kg) or rolipram (Sigma, 30 μM/kg),
and blood samples were collected 1 h later. Cells were
pelleted, suspended, and treated with ammonium-
chloride-potassium (ACK) buffer to lyse erythrocytes.
The cells were then counted and stained with PE-anti-
CD3 antibody for T cells, APC-anti-CD19 antibody for B
cells, FITC-anti-Ly6G antibody for neutrophils, or PE-
Cy7-anti-F4/80 antibody for monocytes, followed by
flow cytometry analysis on BD FACSAria.
Quantification of plasma cortisol by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
Quantitative analysis of hydrocortisone in serum sam-
ples was performed on an LC-MS/MS instrument.
Fludrocortisone acetate was used as a reference stand-
ard; known amounts of this compound were added to
the serum extract prior to the LC injections. The fol-
lowing working parameters were used for the LC-MS/
MS analysis: scan type, MRM (363 → 121 transition
for hydrocortisone and 423 → 239 transition for flu-
drocortisone acetate); polarity, positive; ionization,
ESI; column, C18, 2.1 × 50 mm, 1.8 μm; gradient, so-
lution A = acetonitrile, solution B = 10 mM ammo-
nium acetate in water, 20 → 100 % of A over 5 min
with a flow rate of 0.4 ml/min.
Intravital imaging of T cell egress in lymph nodes
T cells were isolated from lymph nodes and spleens of
normal C57BL/6 mice and treated with a mixture of rat
anti-mouse monoclonal antibodies against CD19, CD32,
and CD16 followed by depletion of antibody-bound cells
with BioMag goat anti-rat IgG (Polysciences Inc.,
Warrington, PA) as previously described [15]. The puri-
fied T cells were stained with 20 μM 5-(and-6)-(((4-
chloromethyl) benzoyl) amino) tetramethylrhodamine
(CMTMR, Invitrogen) for 20 min at 37 °C. The labeled
cells were adoptively transferred to cognate C57BL/6
mice by tail intravenous injection of 1 × 107 cells per
mouse. The recipient mice were then subcutaneously
injected with 15 μg anti-LYVE-1 Ab (R&D Systems)
conjugated with Alexa Fluor-647 (monoclonal antibody
labeling kit, Invitrogen) in a hind footpad, followed by
i.p. injection with 10 mg/kg of hydrocortisone or saline
16 h later. After 2 h of hydrocortisone injection, the
mouse was anesthetized and placed on an electrically
heated plate to maintain the temperature at 36 °C and
had their popliteal lymph nodes exposed by a small skin
incision. The lymph node to be imaged was bathed with
a continuous flow of warm saline in order to maintain a
local temperature at 36 °C during imaging. Intravital im-
aging of the lymph node was performed using a home-
built microscope and the images were acquired using an
in-house developed software [16]. The in vivo confocal
microscope was equipped with three photomultiplier
tubes (PMT, Hamamatsu, R9110) which were optimized
to provide bright images with a high contrast. Each x-y
plane spanned 250 × 250 μm at a resolution of 2 pixels
per μm. Stacks of images were acquired with a z-axis
resolution of 3 μm per section, and time-series images
were obtained in a 20-s interval. To determine whether
a cell was inside, outside, or on the border of a cortical
sinus, its location relative to the sinusoid wall was
assessed in the x-y and/or the z plane. The moving dis-
tances and velocities of the tacking cells were tracked for
each video segment and calculated using ImageJ
software.
Transwell assay for cell migration
T cell migration was analyzed in 48-well micro
chemotaxis chamber (Neuro Probe) as previously de-
scribed [17]. T cells isolated from normal C57BL/6
mice as above were suspended at 1 × 105 cells in
100 μl in RPMI medium supplemented with 3 % fetal
bovine serum (charcoal stripped), 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, and
20 μM of either hydrocortisone or vehicle followed by
adding the cells to the upper chamber of the trans-
well. S1P at 20 nM or vehicle was prepared in the
same medium and added to the lower chamber of the
transwell. Migration was performed for 4 h at 37 °C
in a humidified 5 % CO2 incubator. The number of
migrated cells was determined by counting the cells
in the lower chamber.
S1P administration
S1P (Enzo Life Sciences) was prepared according to the
manufacturer’s instructions. Briefly, S1P was dissolved in
methanol (0.5 mg/ml) and aliquoted, followed by evap-
oration of the solvent under a stream of nitrogen to
deposit a thin film on the inside of the tube. Prior to
use, the aliquots were resuspended in PBS with 4 mg/ml
bovine serum albumin (BSA) to a final concentration of
S1P at 500 μM. The S1P or the vehicle was i.p. injected
into the mice at a dosage of 200 μl per mouse immedi-
ately after TBI.
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Measurement of intracellular cAMP
T cells (2 × 106/ml) freshly isolated from normal C57BL/6
mice were incubated at 37 °C in serum free Aim V medium
(Invitrogen) and pretreated with 10 μM rolipram (Sigma)
or saline for 15 min, followed by a treatment with 100 μM
hydrocortisone or vehicle at 37 °C for 5 min. Intracellular
cAMP was extracted with hydrochloric acid (HCl) and
measured using a cAMP EIA kit following the manufac-
turer’s instruction (Assay Designs).
Real-time quantitative reverse transcription polymerase
chain reaction (qRT-PCR)
Total RNA was extracted from mouse cortex beneath
the impact site 3 days after indicated treatments. The
RNA was reverse transcribed with a high capacity RNA-
to-cDNA kit (Applied Biosystems, Foster City, CA,
USA) and amplified by qRT-PCR) in Roche Lightcycler
480 with a SYBR Green I Master kit (Roche Diagnostics,
Indianapolis, IN, USA). The PCR program was preincu-
bation at 95 °C, 5 min, followed by 45 cycles of 95 °C,
10 s, 60 °C, 10 s, and 72 °C, 10 s. The relative levels of
each target gene were normalized to endogenous β-actin
and calculated using comparative Ct method (ΔΔCt
method) [18]. The primer sequences used were 5′-GAA
GAGCCCATCCTCTGTGA-3′ (forward) and 5′-TTCA
TCTCGGAGCCTGTAGTG-3′ (reverse) for IL-1β; 5′-G
GCTCAGCCAGATGCAGTTAA-3′ (forward) and 5′-C
CTACTCATTGGGATCATCTTGT-3′ (reverse) for CCL
2; 5′- GCCGTCATTTTCTGCCTCA-3′ (forward) and
5′-CGTCCTTGCGAGAGGGATC-3′ (reverse) for CXCL
10; 5′- GGGCTGGCATTGTTCTCTAATGTC-3′ (for-
ward) and 5′-GGATGGTAGCTGGAAGATCGAAAG-3′
(reverse) for ICAM-1; 5′-GTCTACTGAACTTCGGGGT
GAT-3′ (forward) and 5′-ATGATCTGAGTGTGAGGGT
CTG-3′ (reverse) for TNF-α; and 5′-CGAGGCCCAGAG
CAAGAGAG-3′ (forward) and 5′-CGGTTGGCCTTAG
GGTTCAG-3′ (reverse) for β-actin.
Histological examination
Mice were anesthetized and fixed by cardiac perfusion
with cold PBS followed by 10 % formalin. Brains were
carefully removed, fixed overnight in 10 % formalin, and
subjected to histopathological processing and analysis.
Hematoxylin and eosin (H&E)-stained sections of 5-μm-
thickness were scanned by Nanozoomer Slide Scanner
(Olympus America, Center Valley, PA).
Immunofluorescence assays
Acetone-fixed tissue sections were incubated with a
blocking buffer (3 % BSA, 10 % goat serum and 0.4 %
Triton X-100 in PBS) for 1 h at room temperature,
followed with primary antibody diluted in the blocking
buffer at 4 °C overnight. After reaction with a secondary
antibody for 2 h at room temperature and washing, the
slides were mounted with DAPI (4′, 6′-diamidino-2
phenylindole)-containing mounting medium (Invitrogen,
USA). The primary antibody was rabbit anti-Caspase-3
(active) antibody at a 1:100 dilution (Millipore, USA)
and rat anti-CD3 antibody at a 1:100 dilution (BioLegend,
USA). TUNEL staining was carried out by an ApopTag®
Fluorescein In Situ Apoptosis Detection Kit (Millipore,
USA). Images were captured using a confocal microscope
(Olympus FV1000, Olympus, Japan). Percentages of
Caspase-3+ cells were determined by the number of
Caspase-3+ cells relatively to DAPI+ cells in each field of
the 20 randomly selected views of hippocampus area,
which represented a total of ten sections from five injured
brains in each group. Optical density of TUNEL staining
was also calculated in 20 randomly selected views from a
total of ten sections from five injured brains in each group
by ImageJ software.
Statistical analysis
The data are presented as mean ± standard errors of
measurement (SEM). The statistical analysis was per-
formed using the non-parametric Mann-Whitney t test
for comparison between two groups and one-way
ANOVA or two-way ANOVA for comparison among
multiple groups by the Graphpad Prism 6.0 software
(GraphPad Software, CA, USA). A value of P < 0.05 was
considered statistically significant.
Results
Elevation of cortisol but reduction of circulating
lymphocytes following TBI
Our previous study showed that introduction of inflam-
mation worsened secondary brain damage following
mTBI [7]. The mTBI was created by a gentle hit of the
brain with an intact skull and scalp by a standard
controlled impact, which resulted in extensive cell death
at the impact site and significant neurologic severity
score (NSS) ranging from 3 to 5 [7]. However, the
abnormality was fully recovered functionally and histo-
logically in 4 weeks [7], resembling the majority of mTBI
in humans [7]. To determine contributing factors to the
full recovery of mTBI, we measured plasma cortisol and
found that this steroid hormone rose sharply 1 h post-
TBI and declined thereafter (Fig. 1a), similar to what has
been reported in patients suffering from traumatic injury
or after surgery [12, 13]. In parallel to the elevated level
of plasma cortisol was a transient but significantly
diminished number of peripheral lymphocytes, with a
42 % decrease in 1 h after injury and a 20 % decrease in
4 h as compared to control mice (Fig. 1b). The decrease
appeared to be more predominant in T cells than in B
cells, with a 53 % decrease of T cells (Fig. 1c) compared
to only a 28 % decrease of B cells (Fig. 1d) at 1 h post-
injury. There were no significant differences in the
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number of circulating monocytes and neutrophils com-
pared to controls at these time points examined. The
finding that transient lymphocytopenia is inversely cor-
related with the amount of plasma cortisol in the
animals is consistent with the well-documented immune
suppression of cortisol [19].
Exogenous hydrocortisone depresses the number of
leukocytes in the periphery
The inverse correlation between plasma cortisol and the
number of circulating lymphocytes following mTBI
raised an intriguing possibility that plasma cortisol might
be directly responsible for TBI-induced lymphocytope-
nia. To determine this, mice were intraperitoneally
administered hydrocortisone at a dose of 10 mg/kg
followed by enumeration of circulating leukocytes. As
shown in Fig. 1e, exogenous hydrocortisone reduced the
number of leukocytes by 81 % in the periphery over the
control mice in 4 h after administration. The reduction
was most profound in T cells followed by B cells, neu-
trophils, and monocytes, all of which are key cellular
components in the inflammatory cascade (Fig. 1f ). These
results corroborate that the reduced number of periph-
eral lymphocytes is ascribed directly to an elevated level
of endogenous cortisol triggered by TBI.
Hydrocortisone blocks T cell egress from the cortical
sinus in lymph nodes
Although cortisol is well known as a suppressant of
inflammation, the underlying mechanism is not fully
Fig. 1 Inverse relationship between cortisol and lymphocytes in blood following TBI. a Plasma cortisol was quantified before and 1 and 4 h after TBI. In
parallel, the numbers of peripheral lymphocytes (b), T cells (c), and B cells (d) were analyzed at the same time points. A total number of leukocytes (e) or
indicated cells (f) were measured in blood by flow cytometry 4 h after i.p. injection of 10 mg/kg hydrocortisone. Data are expressed as means ± SEM. n= 5
in (a) or 6 in (b, c, d, e, f). Significance was determined using one-way ANOVA (a, b, c, d) or non-parametric Mann-Whitney t test (e, f). *P< 0.05, **P< 0.01,
***P< 0.001, and NS, no significance compared before and after TBI or HC treatment. The experiment was repeated three times with similar results
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understood. Previous studies with 51Cr-labeled lympho-
cytes suggested that a decrease in egress of lymphocytes,
rather than increased homing or cell death, was the
mechanism for the lymphopenia induced by traumatic
stress [20]. In support of this, flow cytometric analysis of
peripheral T and B cells after propidium iodide (PI)
staining did not reveal any significant difference in cell
death in the mice (data not shown). We questioned
whether cortisol blocked lymphocyte egress, lowering
the number of peripheral lymphocytes as did immune
suppression drug FTY720, an analog of S1P [15, 21, 22].
We thus tracked T cell egress in part because T cells
were key contributors to the acute phase of brain injury
[23] and the cells appeared to be more affected by corti-
sol. To this end, purified naive T cells were labeled with
a red vital fluorescent dye CMTMR and infused into
cognate mice followed by subcutaneous injection of
LYVE-1 antibody to mark lymphatic vessels. The cortical
sinusoid region in and adjacent to T cell zones of the
popliteal lymph node was imaged 2 h later after hydro-
cortisone injection by intravital confocal microscopy as
we previously described [15]. As can be seen in Fig. 3a,
the number of T cells was severely reduced within the
cortical sinusoid in the presence compared to the
absence of hydrocortisone (Fig. 2a). Consistent with this,
when tracking 200 cells in 10~15 randomly selected
imaging stacks, we found that the frequency of T cells
entering cortical sinusoids diminished to 15 from 45 %
in the presence compared to the absence of hydrocorti-
sone (Fig. 2b). On the contrary, T cells moving away
from the sinusoids increased from 40 to 75 % in the
mice (Fig. 2c). It can be envisioned that as a majority of
T cells are moving away from the sinusoids, their egress
could be largely prevented, explaining only few T cells
within the sinusoids (Fig. 2a) and a reduced number of
T cells in the periphery (Fig. 1f ). Cortisol also reduced
the ability of T cells to adhere on the sinusoids (Fig. 2e),
in a good agreement with a low entry frequency (Fig. 2b),
because T cell sticking to the sinusoid facilitated entry of
the cell into a sinusoid [15]. During T cell egress, T cells
continuously move toward and crawl along the sinusoid
to search for a “hot entry port” and upon finding the
“port,” the cell enters the sinusoid via it [24, 25], but
many of them move away from the sinusoid prior to
reaching it or after several attempts to associate with or
adhere on the sinusoids [15, 26]. Hydrocortisone
appeared not to affect the number of T cells that crawled
on the sinusoids (Fig. 2d) but greatly increased the num-
ber of T cells moving away the sinusoids (Fig. 2c).
S1P or rolipram increases the number of peripheral T
cells after TBI
We went on to determine whether a high level of S1P,
an egress-promoting agent, could override cortisol-
mediated blockade of T cell egress. We first assessed T
cell migration toward S1P in the presence or absence of
hydrocortisone in vitro, an assay that is commonly used
for assessing S1P function [27]. T cells, along with
hydrocortisone or vehicle, were added to the upper
chamber and S1P or vehicle was included in the lower
chamber of the transwell. As can be seen in Fig. 3a, S1P
significantly increased migration of T cells into the lower
chamber in the presence or absence of hydrocortisone,
suggesting that a high level of S1P may overcome the
inhibitory effect of hydrocortisone and restore the num-
ber of circulating T cells in mice with mTBI. Indeed,
when mice were i.p. administered S1P immediately after
TBI, the number of T cells was completely normalized in
the blood 1 h post-S1P injection in TBI mice (Fig. 3c).
In light of a well-established role for S1P in egress of
lymphocytes, the result corroborates the ability of corti-
sol to block T cell egress, leading to a diminished num-
ber of lymphocytes in circulation immediately after
mTBI. Moreover, the result also confirmed the ability of
hydrocortisone to vigorously blunt T cell migration in
the presence or absence of S1P (Fig. 3a), implicating that
cortisol hampered T cell egress via an intrinsic signaling
pathway of T cells, probably via regulation of cAMP
degradation, a key secondary messenger molecule signal-
ing downstream of the S1P1 receptor as depicted in
Fig. 6. Our previous investigation showed that FTY720
blocked T cell egress by persistent activation of hetero-
trimeric Gαi proteins leading to prolonged inhibition of
cAMP production, apart from induction of S1P1 recep-
tor internalization [15]. We therefore measured cAMP
after hydrocortisone treatment and found that hydrocor-
tisone lowered cAMP levels significantly (Fig. 3b). The
low level of cAMP induced by hydrocortisone was re-
versed by rolipram (Fig. 3b), a cAMP phosphodiesterase
inhibitor that prevents cAMP degradation, corroborating
an antagonistic effect of rolipram on cortisol-mediated
reduction of cAMP, probably via the same target or the
same signaling pathway as illustrated in Fig. 6. In sup-
port, i.p. injection of rolipram immediately after mTBI
also significantly increased the number of T cells in the
periphery, albeit to a much lesser degree in comparison
with S1P (Fig. 3c). The results clearly suggest that hydro-
cortisone blocks T cell egress via a downstream target of
the S1P1 receptor.
A protective role for cortisol in TBI pathogenesis
We next verified positive correlations of circulating lym-
phocytes with inflammation occurring at the impact site
of the brain and directly associated the low inflammation
at the injured site with cortisol-mediated blockade of
lymphocyte egress in mTBI mice. To this end, several
inflammatory mediators, including IL-1β, CCL2,
CXCL10, ICAM-1, and TNF-α, were assayed by qRT-
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PCR at the impact site 3 days after mTBI in the presence
or absence of SIP or rolipram [7]. Our previous study
showed that mTBI up regulated proinflammatory media-
tors at 6 h and dwindled down gradually [7]. Consistent
with this, transcription levels of these proinflammatory
mediators in the mice were not significantly different
from controls (Fig. 4). In contrast, S1P robustly bol-
stered all five inflammatory mediators at the impact
sites, confirming a positive relationship between the
number of circulating lymphocytes and inflammatory re-
sponses occurring at the impact brain tissues (Fig. 4 vs
Fig. 3c). Moreover, out of the five inflammatory
Fig. 2 T cell egress is blocked by hydrocortisone. The representative images taken from control or hydrocortisone (HC)-treated mice are shown in (a).
LYVE-1+ cortical sinuses are shown in blue pseudocolor in order to distinguish them with CMTMR labeled T cells (red) and the representative sinus area is
delineated by a dotted white line. The dotted yellow line outlines the area within 30 μm of distance from the outer boundaries of cortical sinuses. Note: few
T cells within cortical sinus in the presence of HC. Scale bar, 50 μm. Frequencies at which T cells entered (b), moved away (c), crawled on (d), or stuck to (e)
(kept adhering to one point on the sinus wall and never displaced during the imaging period after they engaged the sinus) the cortical sinuses in control
and HC-treated mice were calculated by manually tracking individual cells in each time-lapse image, with a total of 200 cells randomly selected in 10~15
imaging stacks. Each dot represents data from a single time-lapse image, and bars represent the means. Significance was measured using non-parametric
Mann-Whitney t test. *P< 0.05, ***P< 0.001 in the presence or absence of hydrocortisone. Data are combined from two independent experiments each
with two lymph nodes imaged in each treatment. The experiment was repeated two times with similar results
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mediators tested, CCL2 and CXCL10 were also pro-
duced at levels significantly higher in TBI mice given
rolipram than those mice given vehicle control or unin-
jured mice (Fig. 4a–c). Histologically, we observed no
overt alterations in the gross morphology or at a low
magnification on day 7 after injury either in presence or
in absence of S1P or rolipram (Fig. 5a). But a robust
increase in the number of morphologically abnormal
cells was evidenced in the cerebral cortex (B) and hippo-
campus (C) beneath the injured site in TBI mice receiv-
ing S1P compared to TBI controls under a high
magnification (Fig. 5b, c). Notably, healthy cell nuclei
were relatively large consisting of several discernible nu-
cleoli in the nucleoplasm in the cerebral neocortex and
hippocampus in the absence of S1P or normal control
mice (Fig. 5b, c). In contrast, morphologically abnormal
cells were characterized by dark red staining of the nu-
cleoplasm with eosin and presented only at the injured
site (Fig. 5b, c, the third pannel). Although the types of
these abnormal cells were unknown, probably both neu-
rons and glias, the cells appeared undergoing apoptosis
as revealed by two apoptotic markers, Caspase-3 and
TUNEL staining. S1P significantly elevated Caspase-3
activation in the hippocampus (Fig. 5f, i) and TUNEL
staining in the cerebral cortex (Fig 5g, j) in comparison
with TBI only or controls. When rolipram was given,
morphologically abnormal cells were also increased, but
largely limited to the cerebral neocortex (Fig. 5b, c bot-
tom). The apoptosis cells were also found both in the
cortex (Fig 5g, j) and hippocampus (Fig. 5f, i) in TBI
mice receiving rolipram albeit to a much lesser extent in
comparison with S1P, consistent with less effect of roli-
pram on T cell egress in vivo (Fig. 3c). The increase of
cell death at the injured site of the brain was proportion-
ally correlated with T cell infiltration in the tissue as
revealed by anti-CD3 antibody staining (Fig. 5d, e, h). T
cells were hardly presented in the uninjured control
mice or mice with mTBI, in agreement with a complete
recovery of the injury in mTBI mice. However, the num-
ber of T cells increased robustly in the injured brain
after i.p. injection of S1P and to a much lesser degree
rolipram, as a consequence of elevating levels of T cells
Fig. 3 S1P or rolipram increases peripheral T cells in TBI mice. a T cell migration was analyzed in 48-well micro chemotaxis chamber, with 20 μM
hydrocortisone or vehicle in the upper chamber and 20 nM S1P or vehicle in the lower chamber. The number of migrated cells was assessed 4 h later
in the lower chambers. b T cells were pretreated with 10 μM rolipram or saline for 15 min and then with 100 μM hydrocortisone or vehicle treatment
for 5 min, after which intracellular cAMP level was measured. c Peripheral T cells were measured before and 1 h after TBI. S1P or rolipram was i.p.
injected immediately after TBI. Results are expressed as means ± SEM. n = 9 for (a), 6 for (c), or 4 for (b). Significance was determined using two- (a, b)
or one-way (c) ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and NS, no significance compared between indicated groups. The experiment was repeated
three times with similar results
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in circulation. The results conclude that a high level of
peripheral lymphocytes can directly contribute to the
heightened inflammation at the injured site of the brain
in the early phase of TBI.
Discussion
Brain has been viewed as an immune-privileged organ
with little immunological and inflammatory activity
under a physiological condition. This is primarily attrib-
uted to the relative impermeability of the blood-brain
barrier (BBB) to cellular and molecular components of
the immune and inflammatory reactions. However, upon
brain injury, both immediate and secondary dysfunctions
of the BBB occur as a consequence of disrupting the
tight junction complexes and the integrity of the capil-
lary basement membranes [9]. Neutrophils can be found
aggregated in the microvasculature as early as 2 h post
trauma [28]. Their infiltration in damaged neural tissue
commences within 24 h [29], followed by macrophages
within 36–48 h after trauma [30]. T lymphocytes have
been shown to infiltrate the brain within 2–3 days post
injury in a rat TBI model [31]. In those studies, severe
or moderate TBI was induced via opening scalp and
skull and infiltration of inflammatory cells was apparent
Fig. 4 S1P or rolipram exaggerates inflammatory responses in injured brain. IL-1β (a), CCL2 (b), CXCL10 (c), ICAM-1 (d), and TNF-α (e) were analyzed at the
impact site of the cerebral cortex in 3 days after TBI by qRT-PCR. The data are expressed as means ± SEM and normalized to β-actin. n= 5, significance was
measured using one-way ANOVA. *P< 0.05, **P< 0.01, ***P< 0.001 and NS, no significance compared between indicated groups. ###P< 0.001 compared
between TBI and TBI + rolipram in CCL2 and CXCL10 expression level by non-parametric Mann-Whitney t test. The experiment was repeated three times
with similar results
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[28–31], which is likely to be detrimental and associated
with a severe loss of brain tissue and permanent impair-
ment of cognitive neuron function [32]. Cortisol-
mediated suppression of inflammation alone may be too
weak to be effective in severe TBI. In contrast, mTBI
was generated in our study with an intact scalp and skull
Fig. 5 A protective role for cortisol in TBI pathogenesis. a Histologic examination of normal control and injured brain at 7 days after TBI with or without
administration of S1P or rolipram. The impact site was pointed by an arrow. The region of the cerebral cortex was highlighted in a dashed black line square
and enlarged in panel (b); and the hippocampus was outlined by a dashed white line square and magnified in panel (c). Representative results of six mice
in each group. d Representative immunofluorescence results of anti-CD3 antibody staining at hippocampus beneath the injured site and enlarged in panel
(e). f Representative immunofluorescence staining for Caspase-3 expression at hippocampus beneath the injured site. g Representative TUNEL staining for
apoptosis cells at the injury site. Percentages of CD3-positive cells in panel (e), Caspase-3-positive cells in panel (f), and optical density of TUNEL staining in
panel (g) were determined by ImageJ and expressed as means ± SEM in (h), (i), or (j), respectively. n = 6, significance was measured using
one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001 and NS, no significance compared between indicated groups. The experiment was repeated
three times with similar results
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and overt infiltration of inflammatory cells was not
observed, which might be ascribed primarily to cortisol-
mediated blockade of lymphocyte egress. In support of
limiting inflammation at the injured site by cortisol-
mediated blockade on lymphocyte egress at the initial
phase of TBI, when the blockade was abolished by
administering S1P, the number of circulating T cells was
elevated significantly and positively correlated with
increasing inflammatory responses (Fig. 4), T cell infiltra-
tion, and cell death (Fig. 5) at the impact site. The
cortisol-mediated immune suppression observed in this
TBI model is highly relevant to what happens in humans
as a majority of mTBI recovers fully in humans in a few
weeks. The observation hints that immediate immune
suppression following TBI can prevent secondary brain
damage and thus is beneficial to mTBI patients.
Pre-clinical and clinical studies have supported the use
of methylprednisolone, a glucocorticoid drug, as an
acute neuroprotectant after acute spinal cord injury
[33, 34]. Supplement with hydrocortisone post trauma also
improves neurological recovery and leads to beneficial
outcomes [35]. Moreover, progesterone, an indirect
precursor of cortisol, has shown promise to be a neu-
roprotective agent, and it is currently under clinical
trials for the treatment of TBI [36, 37]. The benefit
of inhibiting T cell egress by cortisol is also consistent
with a better outcome of cerebral ischemia in T cell-
deficient mice than in wild-type controls [38]. Moreover,
lymphocyte-deficient Rag1−/− mice are profoundly pro-
tected from stab wound injury of the cortex [39]. Appar-
ently, the linkage between lymphocyte infiltration and
adverse outcome post-TBI contradicts the key role of T
cells in the reparative process. Several studies have shown
that T cells are required for neurogenesis and depletion of
T cells impairs neuronal cell proliferation [5, 40]. Perhaps,
dynamic regulation of the timing and degree of
lymphocyte infiltration is pivotal for its neuroprotec-
tion. Yet, despite the beneficial role, excess cortisol
has adverse effects on mood, cognition, and neurodegen-
eration [41, 42]. It is thus necessary to monitor cortisol
levels post injury and give it preferably to patients with
corticosteroid insufficiency [41]. Alternatively, suboptimal
FTY720 or anti-S1P antibody may be used to suppress
lymphocyte egress at the early phase of TBI to prevent
secondary brain damage [43, 44].
Cortisol is widely recognized for its role in the stress
response and for its physiologic anti-inflammatory effects.
The mechanism underlying its anti-inflammatory effects
may be multifaceted including transcriptional suppression
of proinflammatory genes [45, 46] and inhibition of the
functions of macrophages and neutrophils [47], and the
like. Exogenous glucocorticosteroid administration, espe-
cially in supraphysiological doses, also induces cell death
of immature T and B cells, but mature T cells and
activated B cells are resistant to cell death induced by
cortisol at this low dose [48]. Because the number of
circulating T cells could be restored in traumatic mice by
S1P or rolipram (Fig. 3c), cortisol-induced T lymphocyto-
penia following TBI was unlikely ascribed to cell death.
Our study demonstrating a blockade of T cell egress by
cortisol adds a novel mechanism to our current under-
standing of the anti-inflammatory activity of this steroid
hormone. Substantial evidence has shown that T cell
egress is initiated by binding of S1P to the S1P1 receptor
[21, 49]. The S1P1 receptor is a G protein-coupled recep-
tor and activates exclusively heterotrimeric Gαi proteins
that inhibit adenylate cyclase, leading to brief reduction of
cAMP production followed by normalization and in-
creases of cAMP in the cells (Fig. 6) [50]. On the contrary,
FTY720 binds to the S1P1 receptor and causes the recep-
tor internalization and prolonged reduction of cAMP,
which promotes a sinus-moving away signal and blunts T
cell egress [15]. The level of cAMP was lower in the pres-
ence than in the absence of hydrocortisone (Fig. 3b) but it
was elevated by rolipram. Because rolipram can partially
overcome the inhibitory effect of cortisol and increase
cAMP levels in the presence of cortisol (Fig. 3b), cortisol
may activate cAMP phosphodiesterase (PDE4) either
directly or indirectly (Fig. 6). The secondary messenger
cAMP is a signaling target downstream the S1P1 receptor,
and thus, hydrocortisone inhibits T cell migration (Fig. 3c)
or egress (Fig. 3c), at least in part, by lowering cAMP level
in the cells independent of the S1P1 receptor.
Fig. 6 Schematic illustration of a possible mechanism underlying
cortisol-mediated blockade of T cell egress. cAMP is one of the
important second messengers downstream the S1P1 receptor and
its production takes central part in the control of T cell egress. One
of the cortisol (HC) activities may activate cAMP phosphodiesterase
(PDE4) either directly or indirectly and enhance degradation of cAMP
to 5′-AMP. Cortisol-facilitated degradation of cAMP may be one of
the mechanisms where cortisol compromises T cell egress in the
presence of S1P. On the contrary, rolipram inhibits PDE4, leading to
increased levels of cAMP and promoting T cell egress
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Conclusions
We report here that following mTBI, plasma cortisol
levels are significantly and transiently elevated, which
appears to be directly responsible for the brief lympho-
cytopenia in the periphery by its ability to block lympho-
cyte egress from secondary lymphoid tissues. Abrogation
of cortisol action on lymphocyte egress by injection of
S1P or rolipram was associated with prolonged and in-
creased inflammatory responses and elevated cell death
and T cell infiltration at the injured site of the brain cor-
tex, concluding that lymphocyte infiltration of brain in
the early phase of brain injury is detrimental. The
current work highlights a protective role of cortisol-
induced immune suppression in the early phase of TBI
and offers valuable information with respect to preven-
tion of TBI soon after injury by a blockade of lympho-
cyte egress.
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